SAREPTA THERAPEUTICS, INC. Restricted Cash and Investments
SAREPTA THERAPEUTICS, INC. (SRPT) had Restricted Cash and Investments of $11.13 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Restricted Cash and Investments
us-gaap:RestrictedCashAndInvestments · last filed 2026-08-05
- 2026-06-30: Restricted Cash and Investments $11.13M.
- 2025-12-31: Restricted Cash and Investments $13.13M.
- 2016-12-31: Restricted Cash and Investments $11.50M.
- 2016-09-30: Restricted Cash and Investments $11.50M.
| Period end | Restricted Cash and Investments |
|---|---|
| 2026-06-30 | $11.13M 10-Q · filed 2026-08-05 |
| 2025-12-31 | $13.13M 10-Q · filed 2026-08-05 |
| 2016-12-31 | $11.50M 10-K · filed 2017-02-28 |
| 2016-09-30 | $11.50M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $11.50M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $11.50M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $11.50M 10-K · filed 2016-02-25 |
| 2013-09-30 | $7.80M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $7.80M 10-Q · filed 2013-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |